Laura Giusto, MD
Urology · Owings Mills, MDNPI 1205118296
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $252,135 of the $367,242 with a category attached, or 68.7%. 41 manufacturers reported payments, led by Medtronic at 54.0% of the total. 2025 is the largest year on record at $112,943, more than ten times the $2,595 reported in 2019. Among urology clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 941 payments — averaging $390.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$198K
- Sumitomo Pharma America, Inc.$62K
- Urovant Sciences Inc$42K
- AbbVie$27K
- Bluewind Medical$13K
- Axonics, Inc.$12K
- plus $13K from 35 others
Across 95 payments — averaging $2790.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$137K
- Bluewind Medical$85K
- Laborie Medical Technologies Corp.$24K
- Sumitomo Pharma America, Inc.$13K
- Urovant Sciences Inc$6K
What the payments were for
- Consulting fees$51,57514%
- Speaking & faculty fees$252,13569%
- Travel & lodging$39,67111%
- Food & beverage$23,5996%
- Education$2620%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 454 | $198,348 |
| Sumitomo Pharma America, Inc. | 103 | $62,409 |
| Urovant Sciences Inc | 83 | $41,836 |
| AbbVie(2 entities) | 86 | $27,199 |
| Bluewind Medical | 12 | $12,542 |
| Axonics, Inc. | 46 | $12,359 |
| Valencia Technologies Corporation | 6 | $8,587 |
| Astellas Pharma US Inc | 36 | $648 |
| Coloplast | 18 | $496 |
| Boston Scientific | 9 | $422 |
| Endo Pharmaceuticals Inc. | 8 | $220 |
| Contura, Inc. | 3 | $200 |
| Antares Pharma, Inc. | 10 | $194 |
| Caldera Medical, Inc | 2 | $178 |
| Teleflex LLC | 3 | $168 |
| Immunitybio, Inc. | 1 | $135 |
| Tolmar, Inc. | 5 | $116 |
| Tolmar Pharmaceuticals, Inc. | 5 | $113 |
| Progenics Pharmaceuticals, Inc. | 5 | $113 |
| Merck | 5 | $106 |
| Pfizer | 6 | $101 |
| 180 Medical, Inc. | 4 | $88 |
| Urogen Pharma, Inc. | 1 | $76 |
| Blue Earth Diagnostics | 4 | $70 |
| Rochester Medical Corporation | 2 | $55 |
| Convatec Inc. | 2 | $48 |
| Johnson & Johnson | 2 | $46 |
| Endo USA, Inc. | 3 | $46 |
| Novartis | 2 | $42 |
| AstraZeneca | 1 | $35 |
| Bayer | 2 | $34 |
| Ferring Pharmaceuticals Inc. | 2 | $32 |
| Myriad Genetic Laboratories, Inc. | 2 | $31 |
| ABC Home Medical Supply, Inc. | 1 | $31 |
| Dendreon Pharmaceuticals LLC | 1 | $22 |
| Eisai Inc. | 1 | $19 |
| Halozyme Inc | 1 | $19 |
| Dentsply IH AB | 1 | $16 |
| Tempus AI, Inc | 1 | $16 |
| Amgen | 1 | $15 |
| Renovia Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$153,660
- GEMTESA$101,880
- BOTOX$25,743
- ALTAVIVA$14,447
- REVI$11,588
- eCoin Device Kit$8,440
- Axonics r-SNM System$7,950
- Axonics$2,391
- Bulkamid$1,916
- INTELLIS ADAPTIVESTIM$423
- Saffron$174
- OSTEOCOOL RF ABLATION SYSTEM$169
- UroLift$139
- ANKTIVA$135
- Advantage System$130
- ICONSYNC$117
- ORGOVYX$112
- Desara$110
How this compares
$367,242 in reported general payments places this provider in the 95th percentile of 274 urology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 402 | $436,263 |
| MyrbetriqMirabegron | 100 | $106,791 |
| Estradiol | 352 | $20,337 |
| Oxybutynin Chloride ErOxybutynin Chloride | 117 | $2,849 |
| NitrofurantoinNitrofurantoin Macrocrystal | 90 | $2,640 |
| Methenamine Hippurate | 26 | $1,708 |
| Tolterodine Tartrate ErTolterodine Tartrate | 14 | $1,455 |
| Cephalexin | 73 | $1,079 |
| Ciprofloxacin Hcl | 128 | $559 |
| Tamsulosin Hcl | 33 | $501 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 29 | $422 |
| CefuroximeCefuroxime Axetil | 25 | $409 |
| Solifenacin Succinate | 29 | $408 |
| Fluconazole | 65 | $406 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 128 | $380 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $62,409 | $436,263402 claims |
| Astellas Pharma US IncMyrbetriq | $648 | $106,791100 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 274 urology providers in Maryland.
Other urology in Owings Mills
- Andrew ShapiroOwings Mills$34K
- Justin FangOwings Mills$15K
- Matthew AllawayCumberland$20.6M
- Benjamin LowentrittBaltimore$549K
- Julio DavalosGlen Burnie$490K
- Sankar KausikBel Air$375K
- Amin HeratiBaltimore$160K
- Rian DicksteinHanover$144K
- Max KatesBaltimore$139K
- Arthur BurnettBaltimore$132K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.